• 免疫失调导致抑郁？

有大量证据表明免疫失调和抑郁是相互关联的。如 MDD 与血液和脑脊液（CSF）中促炎细胞因子和急性期蛋白水平升高、适应性免疫反应降低、特异性免疫细胞类型的相对丰度差异、对自身免疫的偏向、小胶质细胞激活增加和其他免疫改变。

• 遗传学与抑郁症

• 生物标志物诊断

• 具有诊断潜力的表型

参考资料

1.Drevets, W.C., Wittenberg, G.M., Bullmore, E.T. et al. Immune targets for therapeutic development in depression: towards precision medicine. Nat Rev Drug Discov 21, 224–244 (2022). https://doi.org/10.1038/s41573-021-00368-1

2.Warden, D., Rush, A. J., Trivedi, M. H., Fava, M. & Wisniewski, S. R. The STAR* D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 9, 449–459 (2007).

3. Uher, R. et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram ａnd nortriptyline. Am. J. Psychiatry 171, 1278–1286 (2014).

4. Haroon, E. et al. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology 95, 43–49 (2018).

5. Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16, 22–34 (2016).

6. Branchi, I. et al. Brain-immune crosstalk in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. 45, 89–107 (2020).

7. Felger, J. C. Role of inflammation in depression ａnd treatment implications. Handb. Exp. Pharmacol. 250, 255–286 (2018).

8. Khandaker, G. M., Pearson, R. M., Zammit, S., Lewis, G. & Jones, P. B. Association of serum interleukin 6 ａnd C-reactive protein in childhood with depression ａnd psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 71, 1121–1128 (2014).

9. Bell, J., Kivimäki, M., Bullmore, E., Steptoe, A. & Carvalho, L. Repeated exposure to systemic inflammation ａnd risk of new depressive symptoms among older adults. Transl. Psychiatry 7, e1208 (2017).

10. Chiu, W., Su, Y., Su, K. & Chen, P. Recurrence of depressive disorders after interferon-induced depression. Transl. Psychiatry 7, e1026 (2017).

11. DNelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).

12. Wray, N. R. et al. Genome-wide association analyses identify 44 risk variants ａnd refine the genetic architecture of major depression. Nat. Genet. 50, 668 (2018).

13. Bull, S. et al. Functional polymorphisms in the interleukin-6 ａnd serotonin transporter genes, ａnd depression ａnd fatigue induced by interferon-α ａnd ribavirin treatment. Mol. Psychiatry 14, 1095–1104 (2009).

原创作者：上海陶术生物科技有限公司